Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Ardent Health Partners, LLC Market Cap
The Ardent Health Partners, LLC (ARDT) share price is expected to increase by 20.47% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered ARDT. Price targets range from $21 at the low end to $27 at the high end. The current analyst consensus for ARDT is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedARDT 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Ardent Health Partners, LLC to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ARDT. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ARDT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Scott Fidel Stephens & Co. | Overweight | $24 | Reiterates | Sep 19, 2024 |
| Timothy Greaves Loop Capital | Buy | $21 | Maintains | Aug 16, 2024 |
| David Macdonald Truist Securities | Buy | $22 | Reiterates | Aug 16, 2024 |
| Scott Fidel Stephens & Co. | Overweight | $24 | Reiterates | Aug 15, 2024 |
Citigroup | Buy | $21 | Initiates | Aug 12, 2024 |
| David Macdonald Truist Securities | Buy | $21 | Initiates | Aug 12, 2024 |
| Lisa Gill JP Morgan | Neutral | $18 | Initiates | Aug 12, 2024 |
| Kevin Fischbeck B of A Securities | Buy | $22 | Initiates | Aug 12, 2024 |
| Timothy Greaves Loop Capital | Buy | $18 | Initiates | Aug 12, 2024 |
| Ann Hynes Mizuho | Outperform | $20 | Initiates | Aug 12, 2024 |
| Craig Hettenbach Morgan Stanley | Overweight | $27 | Initiates | Aug 12, 2024 |
| Ben Hendrix RBC Capital | Outperform | $23 | Initiates | Aug 12, 2024 |
| Whit Mayo Leerink Partners | Outperform | $23 | Initiates | Aug 12, 2024 |
When did it IPO
2024
Staff Count
18,400
Country
United States
Sector/Industry
Healthcare/Medical Care Facilities
CEO
Mr. Martin J. Bonick FACHE, M.H.A.
Market Cap
$2.70B
In 2023, ARDT generated $5.41B in revenue, which was a increase of 5.45% from the previous year. This can be seen as a signal that ARDT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 18 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Ardent Health (NYSE: ARDT) has amended its term loan agreement, reducing the interest rate by 50 basis points to Term SOFR plus 2.75%, while retaining the loan maturity and other terms.
Why It Matters - Ardent Health's loan repricing reduces interest expenses, enhancing profitability and cash flow, which may positively influence stock performance and investor sentiment.
Tue, 03 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Ardent Health (NYSE: ARDT) appointed Dave Styblo as senior vice president of investor relations, overseeing the company's investor relations program. He has over 20 years of investment experience.
Why It Matters - The appointment of Dave Styblo enhances Ardent Health's investor relations, potentially improving communication and confidence among investors, which can positively impact stock performance.
Wed, 28 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Ardent Health Partners will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference from September 4-6, 2024, with CEO Marty Bonick and CFO Alfred Lumsdaine attending.
Why It Matters - Ardent Health's participation in a major healthcare conference highlights its growth potential and strategic positioning, which could influence investor interest and stock performance.
Wed, 14 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Ardent Health Partners reported Q2 2024 results: total revenue of $1.47 billion (up 7.5%), with a net income of $67 million.
Why It Matters - Ardent Health's 7.5% revenue growth and $67 million net income signal strong operational performance, potentially boosting investor confidence and stock valuation.
Mon, 12 Aug 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - Ardent Health Partners Inc. closed its IPO in July, issuing 12 million shares at $16 each, raising approximately $192 million in gross proceeds.
Why It Matters - Ardent Health's IPO raises $192 million, indicating strong investor interest and potential for growth, impacting market sentiment and valuation for similar healthcare companies.
Thu, 01 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Ardent Health Partners, Inc. (NYSE: ARDT) will release its Q2 2024 results on August 14, 2024, after market close, with a conference call scheduled for August 15 at 10:00 a.m. ET.
Why It Matters - Ardent Health's upcoming earnings release and conference call will provide insights into its financial performance and strategic direction, influencing investor sentiment and stock valuation.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
